骨肉瘤基因治疗进展

Advances in Gene Therapy of Osteosarcoma

目的:骨肉瘤是20岁以下儿童、青少年好发的骨原性发恶性肿瘤,恶性度高、预后差.目前骨肉瘤治疗主要以大剂量辅助化疗和手术治疗为主,但治疗后仍具有病情进展快、病灶转移早、肿瘤易复发特点.人类基因组学研究进展表明,骨肉瘤的产生是由宿主基因组体的体细胞介导异常而产生的.基因治疗是一种新的治疗方法,通过基因转移技术将外源正常基因导入到靶细胞中,以纠正或补偿遗传缺陷或疾病异常.随着转基因技术的发展应用,基因治疗骨肉瘤备受学者关注,通过基因治疗有望进一步提高骨肉瘤患者的生存率和预后.本文就近几年骨肉瘤的基因治疗的进展、现状综述.

Osteosarcoma is a primary malignant tumor of bone in children and adolescents under the age of 20,with high malignancy and poor prognosis.At present,the treatment of osteosarcoma is mainly based on high-dose individualized neoadjuvant chemotherapy(preoperative chemotherapy)and surgical treatment,but after treatment,it still has the characteristics of rapid disease progression,early metastasis,tumor recurrence,and difficulty in treatment.Gene therapy is a new and new treatment method,which intends to introduce foreign normal genes into target cells through gene transfer technology to correct or compensate genetic defects or disease abnormalities.With the development and application of transgenic technology,gene therapy for osteosarcoma has attracted much attention from scholars,and gene therapy is expected to further improve the survival rate and prognosis of osteosarcoma patients.This article reviews the progress and current status of gene therapy for osteosarcoma in recent years.